Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor

Background: Recently, modification of T cells with CAR has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a scFv. Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Mahmoud Hassani, Fatemeh Hajari Taheri, Zahra Sharifzadeh, Arash Arashkia, Jamshid Hadjati, Wytske M. van Weerden, Shahriyar Abdoli, Mohammad Hossein Modarressi, Mohsen Abolhassani
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Pasteur Institute of Iran 2020-03-01
Ráidu:	Iranian Biomedical Journal
Fáttát:	chimeric antigen receptor immunotherapy prostate cancer
Liŋkkat:	http://ibj.pasteur.ac.ir/article-1-2922-en.pdf
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!